Retatrutide (RT) 50 mg/vial — 10 Vials/Kit
Retatrutide, commonly abbreviated RT, is an investigational peptide identified by Eli Lilly’s development code LY3437943 (LY-3437943). It is designed as a triple agonist of the GIP, GLP-1, and glucagon receptors and is being investigated in clinical programs involving metabolic and obesity-related conditions.
For your specified package:
50 mg/vial × 10 vials = 500 mg nominal total content per kit.
📋 Product Identification
| 🏷️ Product Field | 🔬 Details |
|---|---|
| 🧬 Product Name | Retatrutide |
| 🔬 Development Code | LY3437943 / LY-3437943 |
| 💊 Strength | 50 mg/vial |
| 📦 Packaging | 10 vials/kit |
| ⚖️ Total Kit Content | 500 mg nominal retatrutide |
| 🧪 CAS No. | 2381089-83-2 |
| 🔖 Alternative Name | LY-3437943 / LY3437943 |
| 🔬 Product Type | Investigational peptide / research compound |
| 🧬 Molecular Classification | GIP/GLP-1/glucagon receptor triple agonist |
| 🏢 Developer | Eli Lilly and Company |
| 🔬 Research Category | Metabolic and cardiometabolic research |
PubChem identifies retatrutide with the development code LY3437943 and CAS 2381089-83-2.
🧬 What Is Retatrutide?
Retatrutide is a synthetic investigational peptide developed by Eli Lilly. Its principal scientific characteristic is triple receptor activity.
The molecule is designed to interact with three hormone receptors:
- 🧬 GIP receptor
- 🧬 GLP-1 receptor
- 🧬 Glucagon receptor
This distinguishes retatrutide from compounds that primarily target one or two of these metabolic pathways.
GIP and GLP-1 are incretin hormones involved in metabolic regulation, while glucagon has important roles in glucose and energy metabolism. Retatrutide’s combined receptor activity is therefore being studied as a potential approach to influencing multiple aspects of metabolic physiology simultaneously.
Lilly describes retatrutide as an investigational once-weekly triple hormone receptor agonist. Clinical trials have evaluated once-weekly subcutaneous administration, but the appropriate administration and dosing of an investigational product should not be inferred from a commercial vial specification.
🔬 How Retatrutide Works
🧬 GIP pathway
Glucose-dependent insulinotropic polypeptide (GIP) is an incretin hormone associated with metabolic signaling. Researchers study GIP receptor activation in relation to glucose and energy metabolism.
🧬 GLP-1 pathway
Glucagon-like peptide-1 (GLP-1) is another incretin hormone. GLP-1 signaling is extensively studied in relation to glucose regulation, appetite, gastrointestinal physiology and body-weight regulation.
🧬 Glucagon pathway
Glucagon plays an important role in glucose homeostasis and energy metabolism. Retatrutide’s activity at the glucagon receptor contributes to its distinctive triple-agonist profile.
🔬 Combined mechanism
The overall research concept can be represented as:
GIP + GLP-1 + Glucagon → Retatrutide (LY3437943)
This multi-receptor mechanism is one of the primary reasons retatrutide has attracted interest in metabolic research.
⚖️ Research Uses
Retatrutide is being investigated in multiple research areas rather than for one single condition.
⚖️ Obesity and body-weight research
Obesity is a major focus of the retatrutide development program. Clinical trials have examined changes in body weight and other metabolic outcomes in adults with obesity or overweight.
In Phase 3 research, Lilly reported substantial reductions in body weight with retatrutide. These findings represent results observed in specific clinical-trial populations and should not be interpreted as guaranteed outcomes for individual users.
🩸 Type 2 diabetes research
Retatrutide is also being studied in people with type 2 diabetes.
Researchers have evaluated outcomes including:
- HbA1c
- Blood-glucose control
- Body weight
- Safety and tolerability
- Metabolic parameters
❤️ Cardiovascular research
Retatrutide is being investigated in populations with obesity and established cardiovascular disease. Researchers are examining whether metabolic improvements may translate into broader cardiovascular outcomes.
🧬 Metabolic liver disease
Another research area is metabolic dysfunction-associated steatotic liver disease (MASLD).
This research reflects growing scientific interest in the relationship between excess body weight, insulin resistance and metabolic liver disease.
😴 Obstructive sleep apnea
Retatrutide is also being investigated in adults with obesity and moderate-to-severe obstructive sleep apnea (OSA).
🦴 Knee osteoarthritis
Clinical research has evaluated retatrutide in adults with obesity or overweight and knee osteoarthritis, examining outcomes related to body weight and osteoarthritis.
🧍 Chronic low-back pain
Retatrutide is also being investigated in relation to chronic low-back pain within Lilly’s broader clinical development program.
⭐ Scientific Advantages
From a research perspective, several characteristics make retatrutide particularly interesting.
| 🔬 Feature | 📖 Research Significance |
|---|---|
| 🧬 Triple receptor activity | Combines GIP, GLP-1 and glucagon receptor activity in one molecule. |
| ⚖️ Weight research | Extensively investigated in obesity and overweight populations. |
| 🩸 Glucose research | Studied for effects on glycemic measures such as HbA1c. |
| ❤️ Cardiometabolic research | Investigated in populations with cardiovascular disease. |
| 🧬 Liver research | Being studied in metabolic liver disease. |
| 😴 OSA research | Investigated in obesity-associated sleep apnea. |
| 🦴 Musculoskeletal research | Studied in obesity-associated knee osteoarthritis. |
| 📚 Broad clinical program | Multiple clinical studies provide data across different populations. |
These are research advantages, not promises of therapeutic benefit.
📦 RT 50 mg/vial — 10 Vials/Kit
Your specified configuration contains:
50 mg × 10 vials = 500 mg nominal total content
| 📦 Package Component | Quantity |
|---|---|
| Retatrutide per vial | 50 mg |
| Number of vials | 10 |
| Total nominal content | 500 mg |
| Development code | LY3437943 |
| Product abbreviation | RT |
The 50 mg/vial designation describes the nominal amount of compound represented by each vial. It is not a recommended clinical dose.
Likewise, purchasing 10 vials does not establish a treatment duration or treatment schedule. Clinical dosing is determined by clinical-trial protocols and, if a medicine is eventually approved, by its regulatory labeling.
🧪 Product Quality Information
For a professional research-product listing, quality specifications should be based on actual supplier/manufacturer documentation.
Where available, you can include:
- 🔬 Peptide purity
- 🧪 Certificate of Analysis (CoA)
- 🧬 Identity testing
- ⚗️ Analytical methodology
- 🧫 Endotoxin testing
- 💧 Residual moisture
- 📦 Batch/Lot number
- 📅 Manufacturing date
- ⏳ Retest/expiration date
- 🧪 Formulation information
Avoid publishing unsupported claims such as “99% purity,” “GMP grade,” “sterile,” “pharmaceutical grade,” or “clinically proven.”
The product page should distinguish between verified analytical specifications and general information about retatrutide.
📊 Detailed Product Specification
| 🏷️ Specification | 🔬 Detailed Description |
|---|---|
| Product Name | Retatrutide |
| Development Code | LY3437943 |
| Alternative Development Code | LY-3437943 |
| Short Name | RT |
| CAS Number | 2381089-83-2 |
| Strength | 50 mg/vial |
| Packaging | 10 vials/kit |
| Total Kit Content | 500 mg nominal |
| Product Type | Investigational peptide / research compound |
| Molecular Classification | GIP/GLP-1/glucagon receptor triple agonist |
| Developer | Eli Lilly and Company |
| Research Category | Metabolic and cardiometabolic research |
| Research Areas | Obesity, type 2 diabetes, cardiovascular/renal outcomes, MASLD, OSA, knee osteoarthritis and chronic low-back pain |
| Clinical Development | Investigational/Phase 3 program |
| Number of Vials | 10 |
| Nominal Amount per Vial | 50 mg |
| Nominal Total per Kit | 500 mg |
⚠️ Regulatory Status
Retatrutide remains an investigational compound and should not be presented on a product page as an FDA-approved medicine.
Therefore, avoid claims such as:
❌ “FDA-approved weight-loss drug”
❌ “Guaranteed weight loss”
❌ “Guaranteed diabetes treatment”
❌ “Safe for everyone”
❌ “No side effects”
❌ “Approved prescription medicine”
Instead, use accurate descriptions such as:
✅ Investigational peptide
✅ Research compound
✅ GIP/GLP-1/glucagon triple agonist
✅ Under clinical investigation
✅ Metabolic research compound
✅ Not currently FDA-approved
Lilly has described retatrutide as investigational and continues to evaluate its safety and efficacy through clinical development.
Retatrutide (LY3437943), also known as RT, is an investigational triple GIP/GLP-1/glucagon receptor agonist developed by Eli Lilly. This configuration contains 10 individual vials specified at 50 mg per vial, providing 500 mg of nominal total peptide content per kit. Retatrutide is being investigated in metabolic and cardiometabolic research, including obesity, type 2 diabetes, cardiovascular outcomes, metabolic liver disease, obstructive sleep apnea and obesity-associated conditions. Intended for legitimate research purposes and not currently FDA-approved for general public use.
- Retatrutide 50mg
- Retatrutide 50 mg vial
- Retatrutide LY3437943
- LY3437943 peptide
- LY-3437943
- RT 50mg
- Retatrutide 10 vial kit
- Retatrutide research peptide
- Retatrutide research compound
- GIP GLP-1 glucagon triple agonist
- Retatrutide metabolic research
- Retatrutide obesity research
- Retatrutide type 2 diabetes research
- Retatrutide 50mg/vial 10 vials
📌 Final Product Summary
RT 50 mg/vial × 10 vials/kit represents a package containing 10 individual vials specified at 50 mg each, giving 500 mg nominal total content.
The active compound is retatrutide, development code LY3437943, also written LY-3437943, with CAS 2381089-83-2. Its defining pharmacological characteristic is simultaneous activity at the GIP, GLP-1 and glucagon receptors.
For catalogue purposes, the clean specification is:
Product Name: Retatrutide
Development Code: LY3437943
Strength: 50 mg/vial
Packaging: 10 vials/kit
Total Kit Content: 500 mg nominal
CAS No.: 2381089-83-2
Alternative Name: LY-3437943
Product Type: Investigational peptide / research compound

